Literature DB >> 9869877

Clinicopathologic features of posttransplant lymphoproliferative disorders.

M A Nalesnik1.   

Abstract

Posttransplant lymphoproliferative disorders (PTLD) are primarily B lymphocyte tumors which are related to the Epstein-Barr virus. Recent studies have more clearly delineated neoplastic from hyperplastic forms of this disease. Factors associated with increased PTLD risk include recipient EBV seronegative status and heavy immunosuppression. The clinical presentation of PTLD is reviewed and lesser known features such as respiratory compromise or localization of tumors to skin are highlighted. The pathologic classifications of PTLD are surveyed and related to one another. Newer approaches to therapy, including the use of monoclonal antibodies and adoptive cellular immunotherapy are discussed.

Entities:  

Mesh:

Year:  1997        PMID: 9869877

Source DB:  PubMed          Journal:  Ann Transplant        ISSN: 1425-9524            Impact factor:   1.530


  5 in total

1.  Epstein-Barr virus represses the FoxO1 transcription factor through latent membrane protein 1 and latent membrane protein 2A.

Authors:  Angharad M Shore; Paul C White; Rosaline C-Y Hui; Abdelkader Essafi; Eric W-F Lam; Martin Rowe; Paul Brennan
Journal:  J Virol       Date:  2006-08-30       Impact factor: 5.103

2.  Epstein-barr virus-negative post-transplant lymphoproliferative diseases: three distinct cases from a single center.

Authors:  Sule Mine Bakanay; Gülşah Kaygusuz; Pervin Topçuoğlu; Sule Sengül; Timur Tunçalı; Kenan Keven; Işınsu Kuzu; Akın Uysal; Mutlu Arat
Journal:  Turk J Haematol       Date:  2014-03-05       Impact factor: 1.831

Review 3.  Post-transplant malignancy: the role of immunosuppression.

Authors:  I Penn
Journal:  Drug Saf       Date:  2000-08       Impact factor: 5.228

4.  Plasma cell myeloma in a renal transplant recipient: A case report and review of literature.

Authors:  S Sharma; C Rana; P B Vinod; A Gupta
Journal:  Indian J Nephrol       Date:  2011-10

5.  Post-transplant lymphoproliferative disease.

Authors:  Vikas R Dharnidharka; Carlos E Araya
Journal:  Pediatr Nephrol       Date:  2007-09-19       Impact factor: 3.714

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.